Uveitis market projected to triple in major markets by 2033

The uveitis treatment market across seven major economies—the USA, France, Germany, Italy, Spain, the UK, and Japan—is projected to grow from $522 million in 2023 to $1.5 billion by 2033, according to a report from data analytics firm GlobalData. This marks an annual growth rate of nearly 11%.

Growth is expected to be driven by the arrival of novel therapies that target different biological pathways and use improved delivery methods, alongside a rise in the diagnosed prevalence of uveitis. In 2023, around 1 million individuals were diagnosed with uveitis across these markets, with that number expected to increase steadily.

Corticosteroids remain the standard of care in the treatment of uveitis, but concerns about side effects such as elevated intraocular pressure and cataract formation have limited their long-term use. Analysts and clinicians highlight the need for longer-acting treatments with safer profiles and new mechanisms of action that could reduce dependence on steroids.